High frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

Pharmacogenomics Journal

Volumn 15, Issue 3, 2015, Pages 288-292

  Apellaniz Ruiz M ^a   Inglada Perez L ^a,b   Naranjo, M E G ^c   Sanchez L ^a   Mancikova, V ^a   Curras Freixes M ^a   De Cubas, A A ^a   Comino Mendez I ^a   Triki, S ^d   Rebai, A ^d   Rasool, M ^e   Moya, G ^f   Grazina, M ^g   Opocher, G ^h   Cascon A ^a,b   Taboada Echalar, P ⁱ   Ingelman Sundberg, M ^j   Carracedo, A ^b,e   Robledo, M ^a,b   Llerena, A ^c   Rodriguez Antona C ^a,b   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^f PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^g UNIVERSITY OF COIMBRA   (Portugal)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ UNIVERSITY OF CHILE   (Chile)

^j KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ALLELE; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; MICROSATELLITE MARKER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPANIARD; ADVERSE DRUG REACTION; ETHNIC GROUP; FOUNDER EFFECT; GENETICS;

ALLELES; CYTOCHROME P-450 CYP3A; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHNIC GROUPS; FOUNDER EFFECT; GENE FREQUENCY; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84929943090     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.67     Document Type: Article

References (24)

1. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141.
2. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360: 1155-1162.
3. Schuetz EG. Lessons from the CYP3A4 promoter. Mol Pharmacol 2004; 65: 279-281.
4. Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007; 15: 251-257.
5. Badyal DK, Dadhich AP. Cytochrome P450 and drug interactions. Indian J Pharmacol 2001: 248-259.
6. Rahmioglu N, Heaton J, Clement G, Gill R, Surdulescu G, Zlobecka K, et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genom 2011; 21: 642-651.
7. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373-388.
8. Penno MB, Dvorchik BH, Vesell ES. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc Natl Acad Sci USA 1981; 78: 5193-5196.
9. Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, et al. Identification and characterization of CYP3A420, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 2006; 79: 339-349.
10. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29: 268-273.
11. Werk AN, Lefeldt S, Bruckmueller H, Hemmrich-Stanisak G, Franke A, Roos M, et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther 2014; 95: 416-422.
12. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005; 338: 299-305.
13. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11: 274-286.
14. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the "missing heritability" problem. Front Genet 2013; 4: 12.
15. Apellániz-Ruiz M, Lee MY, Sánchez L, Gutiérrez-Gutiérrez G, Calvo I, García-Estévez L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. 2014 (submitted).
16. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
17. Reeve JP, Rannala B. DMLE+: Bayesian linkage disequilibrium gene mapping. Bioinformatics 2002; 18: 894-895.
18. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505-514.
19. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
20. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, et al. Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos 2002; 30: 534-540.
21. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007; 117: 3583-3592.
22. Hashimoto M, Kobayashi K, Watanabe M, Kazuki Y, Takehara S, Inaba A, et al. Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J Lipid Res 2013; 54: 2060-2068.
23. Yu AM, Fukamachi K, Krausz KW, Cheung C, Gonzalez FJ. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 2005; 146: 2911-2919.
24. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A422: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013; 14: 47-62.